|
|
Blood, 1 June 2006, Vol. 107, No. 11, pp. 4532-4539.
Prepublished online as a Blood First Edition Paper on February 9, 2006; DOI 10.1182/blood-2005-07-2947.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland,
Ashley Hamilton,
Lucy J. Elrick,
Janet W. Baird,
Elaine K. Allan,
Niove Jordanides,
Martin Barow,
Joanne C. Mountford, and
Tessa L. Holyoake
From the Section of Experimental Haematology and Haemopoietic Stem Cells, Division of Cancer Sciences and Molecular Pathology, University of Glasgow; and the Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in IM-resistant chronic myeloid leukemia (CML). We have previously demonstrated that IM reversibly blocks proliferation but does not induce apoptosis of primitive CML cells. Here, we have attempted to overcome this resistance with dasatinib. Primitive IM-resistant CML cells showed only single-copy BCR-ABL but expressed significantly higher BCR-ABL transcript levels and BCR-ABL protein compared with more mature CML cells (P = .031). In addition, CrKL phosphorylation was higher in the primitive CD34+CD38 than in the total CD34+ population (P = .002). In total CD34+ CML cells, IM inhibited phosphorylation of CrKL at 16 but not 72 hours, consistent with enrichment of an IM-resistant primitive population. CD34+CD38 CML cells proved resistant to IM-induced inhibition of CrKL phosphorylation and apoptosis, whereas dasatinib led to significant inhibition of CrKL phosphorylation. Kinase domain mutations were not detectable in either IM or dasatinib-resistant primitive CML cells. These data confirm that dasatinib is more effective than IM within the CML stem cell compartment; however, the most primitive quiescent CML cells appear to be inherently resistant to both drugs.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al.
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Clin. Cancer Res.,
June 15, 2008;
14(12):
3881 - 3888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice,
April 1, 2008;
21(2):
116 - 125.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Blood,
March 1, 2008;
111(5):
2843 - 2853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Konig, T. L. Holyoake, and R. Bhatia
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Blood,
February 15, 2008;
111(4):
2329 - 2338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang
Toward distinguishing LSCs from HSCs
Blood,
October 1, 2007;
110(7):
2222 - 2223.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. O'Hare, C. A. Eide, and M. W. N. Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood,
October 1, 2007;
110(7):
2242 - 2249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Kwak, J. W. Clark, and B. Chabner
Targeted Agents: The Rules of Combination
Clin. Cancer Res.,
September 15, 2007;
13(18):
5232 - 5237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rahmani, T. K. Nguyen, P. Dent, and S. Grant
The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation
Mol. Pharmacol.,
September 1, 2007;
72(3):
788 - 795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med.,
July 19, 2007;
357(3):
258 - 265.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Modi, T. McDonald, S. Chu, J.-K. Yee, S. J. Forman, and R. Bhatia
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
Blood,
June 15, 2007;
109(12):
5411 - 5421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Konig, N. Hartel, B. Schultheis, M. Schatz, C. Lorentz, J. V. Melo, R. Hehlmann, A. Hochhaus, and P. La Rosee
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells
Haematologica,
June 1, 2007;
92(6):
838 - 841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Rodrigues and M. Sattler
Chronic Myelogenous Leukemia Progenitors Display a Genetically Unstable Personality
J Natl Cancer Inst,
May 2, 2007;
99(9):
662 - 663.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst,
May 2, 2007;
99(9):
680 - 693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Michor
Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors
Stem Cells,
May 1, 2007;
25(5):
1114 - 1118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. G. Jorgensen, E. K. Allan, N. E. Jordanides, J. C. Mountford, and T. L. Holyoake
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Blood,
May 1, 2007;
109(9):
4016 - 4019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. K. Nguyen, M. Rahmani, H. Harada, P. Dent, and S. Grant
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Blood,
May 1, 2007;
109(9):
4006 - 4015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Graf, F. Heidel, S. Tenzer, M. P. Radsak, F. K. Solem, C. M. Britten, C. Huber, T. Fischer, and T. Wolfel
A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells
Blood,
April 1, 2007;
109(7):
2985 - 2988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Shor, E. A. Keschman, F. Y. Lee, C. Muro-Cacho, G. D. Letson, J. C. Trent, W. J. Pledger, and R. Jove
Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival
Cancer Res.,
March 15, 2007;
67(6):
2800 - 2808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, D. Cai, C. Brendel, C. Barett, P. Erben, P. W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation
Blood,
March 1, 2007;
109(5):
2147 - 2155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. I. Lerma, V.-A. Nguyen, T. Wang, A. Tipping, J. V. Melo, D. Kufe, D. J. Austin, and A. Deisseroth
Novel compounds with antiproliferative activity against imatinib-resistant cell lines
Mol. Cancer Ther.,
February 1, 2007;
6(2):
655 - 666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Patel, S. B. Marley, and M. Y. Gordon
Conventional Western blotting techniques will not reliably quantify p210BCR-ABL1 levels in CML mononuclear cells
Blood,
February 1, 2007;
109(3):
1335 - 1335.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Druker, F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W.N. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone, et al.
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
N. Engl. J. Med.,
December 7, 2006;
355(23):
2408 - 2417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Copland, L. Richmond, A. Hamilton, E. K. Allan, J. V. Melo, and T. L. Holyoake
BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
739 - 739.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Jordan, M. L. Guzman, and M. Noble
Cancer stem cells.
N. Engl. J. Med.,
September 21, 2006;
355(12):
1253 - 1261.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E. Jordanides, H. G. Jorgensen, T. L. Holyoake, and J. C. Mountford
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Blood,
August 15, 2006;
108(4):
1370 - 1373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Mauro
Defining and Managing Imatinib Resistance
Hematology,
January 1, 2006;
2006(1):
219 - 225.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|